Project Grant R21AG089655
Award Date
9/15/24
Completion Date
5/31/26
Dollars Obligated
$663K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The National Institute on Aging awarded $3,391,684 under the Aging Research grant program (CFDA 93.866) to Texas A&M University Health Science Center from May 1, 2022 to April 30, 2025. The project aims to test the hypothesis that peripheral insulin-like growth factor-1 (IGF-1), delivered intraperitoneally or orally, will improve acute stroke disability as well as chronic depressive-like behaviors and cognitive impairment post-stroke in a rodent model. Researchers also expect peripheral...
This $834,094 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to advance research on post-stroke cognitive impairment and dementia (PSCID). The funding will support a multi-year effort leveraging a national stroke registry and Medicare data to determine the incidence and prevalence of PSCID, identify associated risk factors, and explore potential pharmacological prevention strategies. Key aspects of the research include a patient-centered approach,...
The National Institute on Aging (NIA) awarded a Project Grant under the Aging Research Federal Grant Program (CFDA 93.866) to the University of Texas Health Science Center at Houston (UTHealth) totaling $644,881 to investigate a novel blood substitution approach for treating acute ischemia in the aged brain. The research aims to demonstrate the potential of blood substitution therapy to reduce stroke severity by removing neutrophils and matrix metalloproteinase-9 (MMP-9) from the blood,...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $654,238 to The University of Texas Health Science Center at San Antonio to study the role of senescent cells in Alzheimer's disease and related dementias (ADRD). The primary goals are to: Identify molecular markers and changes in the microenvironment of senescent neurons compared to healthy neurons, with a focus on their contribution to neuronal death in brain aging and ADRD (R21 phase). Use...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to gain a mechanistic understanding of the role of cellular senescence in the pathogenesis of Alzheimer's disease (AD). The $460,625 grant will fund research at the University of Massachusetts Medical School to dissect the separate P53/P21 and P16 senescence pathways and their functional consequences in AD using human induced pluripotent stem cell-based models. The 2-year project will produce...
The National Institute on Aging, part of the Department of Health and Human Services' National Institutes of Health, awarded $3,387,438 under the Aging Research program (CFDA 93.866) to The Ohio State University Office of Sponsored Programs on September 19, 2022. The three-year project grant aims to develop and test a novel neuroprotective agent, TAT-M2NX, to provide both acute and sustained synaptic protection following acute ischemic stroke. The research seeks to characterize the agent's...
This $454,225 Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) will support research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop new methods for assessing "effective reserve" in patients with acute ischemic stroke. The key objectives are to: 1) investigate the concept of effective reserve and its feasibility in acute ischemic stroke patients using two large...
This $399,345 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate novel therapeutic strategies for improving outcomes of acute ischemic stroke (AIS) in older mice. The key research objectives are to: (1) Rejuvenate age-associated reductions in endothelial cell (EC) autophagy and restore EC glucose transporter 1 (GLUT1) expression to improve EC function and AIS outcomes; and (2) Evaluate whether the approved drug bryostatin-1 can...
This federal Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $640,906 to the University of Wisconsin - Madison to elucidate the cerebrovascular disease pathways that contribute to cognitive decline. The project aims to utilize advanced neuroimaging techniques to characterize the impact of vascular disease processes, including vascular stiffness and decreased flow tone, on brain tissue integrity and cognition in the presence...
This Federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) for $146,922 will support a study to evaluate the relationship between life-space and long-term cognitive decline after stroke. The key objectives are to: (1) estimate the effects of life-space components on cognitive decline following stroke in a large observational cohort, (2) characterize the life-space of stroke survivors using geolocation data, and (3) prospectively evaluate the effect of...